Research programme: Ebola therapeutics - Intellimedix

Drug Profile

Research programme: Ebola therapeutics - Intellimedix

Latest Information Update: 20 Oct 2014

Price : $50

At a glance

  • Originator Intellimedix
  • Developer Georgia Institute of Technology; Intellimedix
  • Class
  • Mechanism of Action Protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Ebola virus infections

Most Recent Events

  • 16 Oct 2014 Early research in Ebola virus infections in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top